Does UnitedHealthcare Cover Jardiance (Empagliflozin)?

UnitedHealthcare Formulary Placement for Jardiance

On most UnitedHealthcare commercial PPO and HMO plans, Jardiance (empagliflozin 10 mg and 25 mg tablets) sits on Tier 3 as a preferred brand medication. Tier 3 drugs carry higher copays than Tier 1 generics or Tier 2 preferred generics, but they cost less out-of-pocket than Tier 4 non-preferred brands.

Exact copay amounts vary by employer-sponsored benefit design. A typical UHC Tier 3 copay ranges from $40 to $75 per 30-day fill, though high-deductible health plans (HDHPs) require members to meet the full deductible before copay pricing applies. Members enrolled in UHC Medicare Advantage plans may see different tier placement; some MA-PD formularies list empagliflozin on Tier 4, which can push monthly out-of-pocket costs above $100 before reaching the catastrophic coverage phase.

To confirm your specific plan's tier and copay, log in to myuhc.com or call the number on the back of your member ID card. Formulary documents update quarterly, so the tier you see today could shift at the next formulary refresh. The FDA-approved prescribing information for empagliflozin lists three distinct indications, and coverage eligibility depends on which one your prescriber documents [1].

Prior Authorization Requirements

UnitedHealthcare requires prior authorization before dispensing Jardiance. The difficulty level is moderate, meaning most PA requests are processed within 48 to 72 hours, but some cases need additional clinical documentation.

Your prescriber's office will submit a PA request to UHC's pharmacy benefit manager (typically OptumRx for commercial plans). The request must include a confirmed diagnosis of type 2 diabetes mellitus, heart failure (NYHA class II-IV with left ventricular ejection fraction of 40% or less), or chronic kidney disease with eGFR between 20 and 90 mL/min/1.73 m². UHC reviewers verify that the requested indication matches an FDA-approved use.

Standard documentation the PA form requires:

• Current HbA1c level (for type 2 diabetes requests)
• List of previously tried and failed diabetes medications, with dates and reasons for discontinuation
• Recent echocardiogram results showing LVEF (for heart failure requests)
• Most recent serum creatinine and eGFR values (for CKD requests)
• Prescriber attestation that the patient has no contraindications, including a history of diabetic ketoacidosis or severe hypersensitivity to empagliflozin

In the landmark EMPA-REG OUTCOME trial (N=7,020), empagliflozin reduced cardiovascular death by 38% in patients with type 2 diabetes and established cardiovascular disease (HR 0.62, 95% CI 0.49-0.77) [2]. Citing this trial data in the PA letter can strengthen a request for patients with coexisting cardiovascular risk, because UHC clinical reviewers use evidence-based criteria that weight cardiovascular outcome trial results.

If the PA is denied, OptumRx sends written notification within one business day. That denial letter includes the specific clinical rationale and instructions for appeal.

Step Therapy: What UHC Expects You to Try First

Many UnitedHealthcare plans enforce step therapy for SGLT2 inhibitors, including Jardiance. Step therapy means the plan requires documentation that the patient tried (and failed or cannot tolerate) one or more lower-cost medications before approving a higher-tier drug.

For type 2 diabetes, UHC's standard step therapy protocol requires a trial of metformin at maximally tolerated doses (typically 1,500 to 2,000 mg daily) for at least 90 days, unless metformin is contraindicated. Contraindications that satisfy step therapy without a metformin trial include eGFR below 30 mL/min/1.73 m², documented lactic acidosis history, or severe GI intolerance at doses below 500 mg daily.

Some employer-customized plans also require a trial of a sulfonylurea or a preferred DPP-4 inhibitor before approving an SGLT2 inhibitor. Your prescriber can call the OptumRx PA line to determine your plan's specific step requirements.

For heart failure and CKD indications, step therapy protocols are less common. The 2022 AHA/ACC/HFSA heart failure guideline designates SGLT2 inhibitors as a Class I recommendation for heart failure with reduced ejection fraction, regardless of diabetes status [3]. When a cardiologist or nephrologist documents these indications, UHC reviewers often waive the diabetes-specific step therapy requirement. This is a distinction worth pressing with the PA team if your prescriber writes for heart failure or CKD rather than glycemic control.

How to Appeal a UnitedHealthcare Denial of Jardiance

A denied PA is not the final word. UnitedHealthcare offers a structured, two-level internal appeal process followed by an external independent review.

Level 1 internal appeal. You or your prescriber must file within 180 days of the denial notice. Submit a written appeal letter, updated clinical notes, and any supporting literature. Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "SGLT2 inhibitors have moved from optional add-ons to guideline-recommended therapy for patients with cardiovascular or renal comorbidities. Payers should align coverage with the evidence." Including a peer-to-peer review request lets your physician speak directly with the UHC medical director reviewing the case. Level 1 decisions arrive within 30 calendar days for standard appeals or 72 hours for expedited (urgent) appeals.

Level 2 internal appeal. If Level 1 fails, submit a second appeal within 60 days of the Level 1 decision. Include any new evidence, such as an updated HbA1c showing inadequate control on current therapy, documented adverse effects from step therapy agents, or a letter of medical necessity from a specialist.

External review. After exhausting both internal levels, members can request an external review by an independent review organization (IRO). The IRO is a third party with no financial relationship to UHC. State insurance regulations govern external review timelines, but federal law requires a decision within 45 days for standard cases and 72 hours for urgent cases. The IRO's decision is binding on UHC.

The EMPA-KIDNEY trial (N=6,609) demonstrated that empagliflozin reduced the composite of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64-0.82) in patients with CKD [4]. Appeals for CKD-indication coverage should reference this trial prominently, as it was published after many formulary PA criteria were last updated.

Jardiance Cost Breakdown With and Without UHC Coverage

Understanding the full cost picture helps you choose the lowest out-of-pocket path. Jardiance has no generic equivalent, so brand pricing applies across all pharmacies.

Without any insurance, Jardiance 10 mg or 25 mg (30-tablet supply) lists at approximately $680 per month. Cash-pay discount programs through GoodRx or RxSaver sometimes bring this down to $550 to $610, depending on pharmacy location.

With UHC commercial coverage after PA approval, most members pay between $40 and $75 per fill at Tier 3. Members in high-deductible plans pay the full negotiated rate (often $450 to $550) until reaching their deductible.

Boehringer Ingelheim, the manufacturer of Jardiance, offers a savings card program that reduces the copay to as low as $10 per month for eligible patients with commercial insurance. The card covers up to $6,000 per year in out-of-pocket costs. Key eligibility rules: the patient must have commercial insurance (not Medicare, Medicaid, or Tricare), must have a valid prescription, and must fill at a participating retail pharmacy.

For UHC Medicare Advantage members, the manufacturer savings card does not apply. Instead, the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs (effective since January 2025) limits total yearly spending. The Part D Medicare Prescription Payment Plan also allows members to spread costs across monthly installments [5].

SGLT2 Inhibitor Alternatives on the UHC Formulary

If Jardiance is denied or the copay remains too high, several alternatives within the SGLT2 inhibitor class may receive more favorable formulary treatment on specific UHC plans.

Dapagliflozin (Farxiga). Some UHC plans list dapagliflozin on Tier 3 with a lower copay or with less restrictive PA criteria. Dapagliflozin carries FDA approvals for type 2 diabetes, heart failure (HFrEF and HFpEF), and CKD, similar to empagliflozin. The DAPA-HF trial (N=4,744) showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65-0.85) [6].

Canagliflozin (Invokana). Canagliflozin sometimes appears on Tier 2 on older UHC formulary designs. The CREDENCE trial (N=4,401) demonstrated a 30% reduction in the renal composite endpoint (HR 0.70, 95% CI 0.59-0.82) [7]. Canagliflozin does carry a boxed warning about increased amputation risk, which may limit prescriber preference.

Ertugliflozin (Steglatro). Ertugliflozin is occasionally placed on a preferred tier, but it lacks dedicated heart failure or CKD outcome trial data comparable to empagliflozin or dapagliflozin.

If your physician believes empagliflozin is specifically required (for example, based on the EMPA-REG OUTCOME cardiovascular mortality data), documenting why alternatives are clinically inappropriate strengthens the appeal.

Tips for Smooth Prior Authorization Approval

Getting a PA approved on the first attempt saves weeks of back-and-forth. These strategies increase the likelihood of approval.

Have your prescriber submit the PA before you arrive at the pharmacy. Reactive PAs (initiated when the pharmacist runs the claim and gets a rejection) take longer to process and create gaps in therapy. Proactive submission through the OptumRx provider portal or fax line typically yields a determination within 48 hours.

Include all supporting lab work dated within the last 90 days. Stale labs are the most common reason for PA information requests, which reset the review clock. For diabetes, submit the most recent HbA1c. For heart failure, include a recent echocardiogram report. For CKD, include a comprehensive metabolic panel with eGFR and a urine albumin-to-creatinine ratio.

Document step therapy compliance explicitly. If the patient tried metformin 2,000 mg daily from January through April and discontinued due to persistent diarrhea, write that exact sentence in the PA notes. Vague statements like "metformin intolerance" are frequently returned for clarification.

Request peer-to-peer review immediately after any initial denial rather than waiting for a formal appeal. Peer-to-peer conversations between your prescribing physician and the UHC medical director resolve roughly 40% of initial denials without requiring a written Level 1 appeal, according to data from the American Medical Association's 2024 Prior Authorization Physician Survey [8].

Dr. Jack Lewin, former CEO of the American College of Cardiology, has noted: "The gap between guideline recommendations and payer coverage for SGLT2 inhibitors creates real harm for patients who face months of delays before receiving evidence-based therapy."

Special Situations: Medicare Advantage and Exchange Plans

UnitedHealthcare Medicare Advantage (MA) plans and Affordable Care Act (ACA) exchange plans handle Jardiance coverage differently from employer-sponsored commercial plans.

Medicare Advantage. MA-PD plans use a separate formulary from commercial UHC plans. Jardiance may appear on Tier 4 (non-preferred brand) in some MA-PD formularies, pushing monthly costs higher before catastrophic coverage begins. The 2025 Part D redesign capped annual out-of-pocket drug spending at $2,000, which limits total yearly exposure regardless of tier placement [5]. Members hitting the cap early in the year pay $0 for remaining fills.

ACA exchange plans. UHC exchange plans sold through healthcare.gov marketplaces use Essential Health Benefit drug formularies. These formularies must cover at least one drug per pharmacologic class. Since SGLT2 inhibitors are a defined class, at least one member (often dapagliflozin or empagliflozin) must be covered. If the covered SGLT2 inhibitor is not Jardiance, your prescriber can submit a formulary exception request with clinical justification for why the covered alternative is inappropriate.

Medicaid managed care. In states where UHC administers Medicaid managed care, Jardiance coverage depends on the state's preferred drug list. Several state Medicaid programs prefer dapagliflozin over empagliflozin based on net cost negotiations with manufacturers.

Regardless of plan type, the 2024 ADA Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or CKD with albuminuria, independent of HbA1c level [9]. This guideline language supports coverage requests across all UHC plan types.

Timeline: From Prescription to First Fill

Knowing the typical timeline helps set expectations and prevent therapy gaps.

Day 1. Prescriber writes the Jardiance prescription and submits PA to OptumRx.

Days 2-3. OptumRx reviews and either approves, requests additional information, or denies. Approval triggers an authorization code sent to your pharmacy.

Day 3-4 (if approved). Fill the prescription at any in-network pharmacy. Apply the manufacturer savings card at the register to reduce your copay.

Days 4-10 (if additional info requested). Prescriber submits supplemental documentation. Review clock resets for another 48-72 hours.

Days 10-14 (if denied). Prescriber requests peer-to-peer review or files Level 1 appeal.

Days 14-44 (if appealed). Level 1 appeal decision within 30 calendar days.

For patients switching from another diabetes medication, prescribers can request an expedited PA (72-hour turnaround) by documenting clinical urgency, such as HbA1c above 9% or recent hospitalization for heart failure exacerbation.

Patients with an active Jardiance prescription reaching a formulary change at annual renewal should ask their prescriber to submit the new year's PA in December, before the January 1 formulary transition date, to prevent fill gaps at the start of the benefit year.